Market closedNon-fractional
Oric Pharmaceuticals/ORIC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
Ticker
ORIC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
102
Website
www.oricpharma.com
ORIC Metrics
BasicAdvanced
$758M
Market cap
-
P/E ratio
-$1.78
EPS
1.18
Beta
-
Dividend rate
Price and volume
Market cap
$758M
Beta
1.18
Financial strength
Current ratio
21.307
Quick ratio
20.827
Long term debt to equity
2.109
Total debt to equity
2.109
Management effectiveness
Return on assets (TTM)
-24.70%
Return on equity (TTM)
-38.30%
Valuation
Price to book
2.32
Price to tangible book (TTM)
2.32
Price to free cash flow (TTM)
-6.675
Growth
Earnings per share change (TTM)
-18.47%
3-year earnings per share growth (CAGR)
-12.42%
What the Analysts think about ORIC
Analyst Ratings
Majority rating from 9 analysts.
ORIC Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$25M
-11.66%
Profit margin
0.00%
NaN%
ORIC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.50
-$0.44
-$0.49
-$0.37
-
Expected
-$0.57
-$0.46
-$0.49
-$0.44
-$0.41
Surprise
-12.15%
-4.74%
0.73%
-15.16%
-
ORIC News
AllArticlesVideos
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
GlobeNewsWire·1 week ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oric Pharmaceuticals stock?
Oric Pharmaceuticals (ORIC) has a market cap of $758M as of July 27, 2024.
What is the P/E ratio for Oric Pharmaceuticals stock?
The price to earnings (P/E) ratio for Oric Pharmaceuticals (ORIC) stock is 0 as of July 27, 2024.
Does Oric Pharmaceuticals stock pay dividends?
No, Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Oric Pharmaceuticals dividend payment date?
Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders.
What is the beta indicator for Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Oric Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.